Published in J Thromb Haemost on November 01, 2011
Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open (2013) 1.40
Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups. Thrombosis (2013) 1.20
Optimizing the dose of dabigatran etexilate. Br J Clin Pharmacol (2012) 1.20
Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol (2013) 0.98
Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles? Br J Clin Pharmacol (2012) 0.97
Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol (2013) 0.95
Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations. Biomed Res Int (2015) 0.95
Coagulation assessment with the new generation of oral anticoagulants. Emerg Med J (2015) 0.93
Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran. Br J Clin Pharmacol (2014) 0.92
Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis (2016) 0.91
No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke. PLoS One (2012) 0.90
A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. Br J Clin Pharmacol (2014) 0.89
New oral anticoagulants: discussion on monitoring and adherence should start now! Thromb J (2013) 0.88
Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban. Thrombosis (2012) 0.87
New oral anticoagulants for atrial fibrillation: are they worth the risk? P T (2014) 0.87
Pharmacometric characterization of dabigatran hemodialysis. Clin Pharmacokinet (2013) 0.86
Translational insights into traumatic brain injury occurring during dabigatran or warfarin anticoagulation. J Cereb Blood Flow Metab (2014) 0.83
A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. Br J Clin Pharmacol (2013) 0.82
Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban. Herz (2015) 0.79
Concerns regarding the use of dabigatran for stroke prevention in atrial fibrillation. Pharmaceuticals (Basel) (2012) 0.78
Impact of renal function deterioration on adverse events during anticoagulation therapy using non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Heart Vessels (2015) 0.78
The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies. Br J Clin Pharmacol (2016) 0.77
Monitoring anticoagulant therapy with new oral agents. World J Methodol (2015) 0.77
Frequency and predictors of bleeding complications associated with anti-coagulant therapy using dabigatran in Japanese patients with atrial fibrillation. Am J Cardiovasc Dis (2014) 0.77
Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting. Thromb J (2016) 0.76
The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit-risk ratio. Ther Adv Neurol Disord (2015) 0.76
Enhanced elimination of dabigatran through extracorporeal methods. J Med Toxicol (2015) 0.76
Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants. Biomed Res Int (2014) 0.76
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy. Ann Pharmacother (2016) 0.75
Update on Anticoagulation: What the Interventional Radiologist Needs to Know. Semin Intervent Radiol (2016) 0.75
Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance. Am J Med (2017) 0.75
Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. CMAJ (2017) 0.75
Exposure-response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation. Br J Clin Pharmacol (2015) 0.75
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial: a rebuttal. J Thromb Haemost (2012) 0.75
Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit. Clin Kidney J (2015) 0.75
Potential use of NOACs in developing countries: pros and cons. Eur J Clin Pharmacol (2014) 0.75
Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs. Drug Saf (2017) 0.75
The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review. Clin Res Cardiol (2017) 0.75
Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations. Int J Nephrol Renovasc Dis (2017) 0.75
2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J Arrhythm (2017) 0.75
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med (2001) 20.20
Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis (1985) 19.03
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 15.32
Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J (1985) 9.28
The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care (1999) 9.16
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA (2001) 9.16
Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA (2001) 8.80
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet (2001) 8.54
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med (1992) 8.38
Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE) Lancet (2000) 8.01
Why do we need some large, simple randomized trials? Stat Med (1985) 7.67
An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation (1989) 6.87
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet (2009) 6.83
Emerging epidemic of cardiovascular disease in developing countries. Circulation (1998) 6.41
Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med (2001) 6.38
Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med (1988) 5.81
The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia (2005) 4.45
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet (1999) 4.36
Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med (2000) 4.35
Risk factors for acute myocardial infarction in Indians: a case-control study. Lancet (1996) 4.28
Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. JAMA (1993) 4.01
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation (2001) 3.96
Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet (1998) 3.79
Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet (2002) 3.77
Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation (1990) 3.72
Coronary heart disease and its risk factors in first-generation immigrant Asian Indians to the United States of America. Indian Heart J (1996) 3.66
Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med (1999) 3.63
Epidemiology and causation of coronary heart disease and stroke in India. Heart (2008) 3.60
Health and peace: time for a new discipline. Lancet (2001) 3.52
Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med (2000) 3.32
Cardiovascular and cancer mortality among Canadians of European, south Asian and Chinese origin from 1979 to 1993: an analysis of 1.2 million deaths. CMAJ (1999) 3.18
Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation (2000) 3.12
Cardiac arrhythmia and conduction disturbances during sleep in 400 patients with sleep apnea syndrome. Am J Cardiol (1983) 3.01
Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group. Circulation (1996) 2.91
Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ (1996) 2.90
Prevalence of coronary artery disease in Asian Indians. Am J Cardiol (1992) 2.90
Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. J Am Coll Cardiol (2001) 2.87
Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. BMJ (1991) 2.81
Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation (2007) 2.76
Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet (2000) 2.74
Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS. Eur Heart J (2004) 2.67
Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation (1994) 2.61
Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation (1997) 2.43
Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA (2001) 2.37
The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data. Ann Intern Med (1995) 2.32
Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation (2001) 2.30
Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ (1989) 2.27
Overview of randomised trials of diuretics in pregnancy. Br Med J (Clin Res Ed) (1985) 2.27
Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis. Lancet (2000) 2.17
Potentially modifiable risk factors associated with myocardial infarction in China: the INTERHEART China study. Heart (2009) 2.16
Sensitive and specific method for rapid identification of Streptococcus pneumoniae using real-time fluorescence PCR. J Clin Microbiol (2001) 2.15
Intravenous magnesium in acute myocardial infarction. An effective, safe, simple, and inexpensive intervention. Circulation (1993) 2.15
Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension (2001) 2.15
Acute precipitants of congestive heart failure exacerbations. Arch Intern Med (2001) 2.11
How should results from completed studies influence ongoing clinical trials? The CAFA Study experience. Ann Intern Med (1991) 2.06
Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. J Am Coll Cardiol (2001) 2.05
Stroke prevention in nonvalvular atrial fibrillation. Ann Intern Med (1991) 2.01
Early intravenous atenolol treatment in suspected acute myocardial infarction. Preliminary report of a randomised trial. Lancet (1980) 2.00
Preventing stroke in atrial fibrillation: why are so many eligible patients not receiving anticoagulant therapy? CMAJ (1999) 1.95
Can medicine prevent war? Imaginative thinking shows that it might. BMJ (1999) 1.95
Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol (1991) 1.94
Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators. J Am Coll Cardiol (2001) 1.92
Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J (2004) 1.90
Early statin treatment following acute myocardial infarction and 1-year survival. JAMA (2001) 1.89
Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Control Clin Trials (1997) 1.88
Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J (2000) 1.88
Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials. Circulation (1995) 1.85
New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation (2001) 1.83
Nonrheumatic atrial fibrillation. Risk of stroke and role of antithrombotic therapy. Circulation (1991) 1.83
Magnesium in acute myocardial infarction. BMJ (1995) 1.80
Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J (1999) 1.76
Ethnic differences in the relationships between obesity and glucose-metabolic abnormalities: a cross-sectional population-based study. Int J Obes (Lond) (2005) 1.72
The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J (2000) 1.72
The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee's final decision on end-points. Eur Heart J (1999) 1.72
Cost-effectiveness of the implantable cardioverter-defibrillator: results from the Canadian Implantable Defibrillator Study (CIDS). Circulation (2001) 1.70
Post-myocardial infarction mortality in patients with ventricular premature depolarizations. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study. Circulation (1991) 1.68
Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register. J Intern Med (2009) 1.65
Risk stratification in unstable coronary artery disease. Additive value of troponin T determinations and pre-discharge exercise tests. FRISK Study Group. Eur Heart J (1997) 1.65
Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. SOLVD Investigations. Studies of Left Ventricular Dysfunction Investigators. Am J Cardiol (1996) 1.64
Increased risk of acute myocardial infarction associated with beedi and cigarette smoking in Indians: final report on tobacco risks from a case-control study. Indian Heart J (2002) 1.62
Education and risk for acute myocardial infarction in 52 high, middle and low-income countries: INTERHEART case-control study. Heart (2009) 1.61
Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA (1993) 1.60
Effect of vasodilators on survival in chronic congestive heart failure. Am J Cardiol (1985) 1.60
Structure and targeted mutagenesis of the gene encoding 8-kDa subunit of photosystem I from the cyanobacterium Synechocystis sp. PCC 6803. J Biol Chem (1989) 1.60
Increased winter mortality from acute myocardial infarction and stroke: the effect of age. J Am Coll Cardiol (1999) 1.59
Impact of right ventricular involvement on mortality and morbidity in patients with inferior myocardial infarction. J Am Coll Cardiol (2001) 1.58
Meeting of the International Working Group on Coronary Artery Disease in South Asians. 24 March 1996, Orlando, Florida, USA. Indian Heart J (1997) 1.58